ロード中...
Bisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases
Whether bisphosphonates could enhance the effect of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in non-small-cell lung cancer (NSCLC) patients with EGFR mutation and bone metastases (BM) remains unknown. EGFR mutation status were collected from 1560 patients with NSCLC...
保存先:
| 出版年: | Sci Rep |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Nature Publishing Group
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5314405/ https://ncbi.nlm.nih.gov/pubmed/28211502 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep42979 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|